Medicare Enrolled
Dr. Kenneth Johnson, MD
Hematology & Oncology · Chula Vista, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Johnson from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Johnson?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Johnson
Dr. Kenneth Johnson is a hematology & oncology specialist in Chula Vista, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Johnson performed 180,398 Medicare services across 2,104 unique beneficiaries.
Between the years covered by Open Payments, Dr. Johnson received a total of $19,582 from 81 pharmaceutical and/or device companies across 600 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Johnson is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 3% volume in CA
$19,582 industry payments
Medicare Practice Summary
Medicare Utilization ↗180,398
Medicare services
Top 3% in CA for hematology & oncology
2,104
Unique beneficiaries
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~9,495 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
90,750 | $1 | $2 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
77,100 | $2 | $10 |
| Denosumab injection (Prolia/Xgeva) | 5,940 | $19 | $28 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,654 | $8 | $16 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,606 | $8 | $10 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
993 | $95 | $185 |
| Injection, granisetron hydrochloride, 100 mcg | 620 | $0 | $80 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
446 | $12 | $45 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
192 | $97 | $170 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
181 | $116 | $300 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
119 | $32 | $89 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
108 | $1 | $10 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
105 | $71 | $130 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 91 | $134 | $2,100 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
86 | $14 | $50 |
| New patient office visit, complex (60-74 min) | 83 | $162 | $335 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
73 | $25 | $70 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
69 | $28 | $66 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
68 | $26 | $55 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
35 | $138 | $265 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
26 | $89 | $175 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
26 | $115 | $320 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
14 | $145 | $240 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
13 | $107 | $351 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
50.4% high complexity
46.9% medium
2.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$19,582
Total received (2018-2024)
Avg $2,797/year across 7 years
Top 21% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
81
Companies
600
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,675 (59.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$6,044 (30.9%)
Other
Charitable contributions, space rental, and other categories
$1,863 (9.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,002
2023
$1,220
2022
$1,830
2021
$2,801
2020
$1,850
2019
$8,053
2018
$2,826
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Lilly USA, LLC
$126
Genentech USA, Inc.
$116
PFIZER INC.
$114
AstraZeneca Pharmaceuticals LP
$76
Novartis Pharmaceuticals Corporation
$56
GlaxoSmithKline, LLC.
$53
Janssen Biotech, Inc.
$48
Daiichi Sankyo Inc.
$48
GENZYME CORPORATION
$37
Alexion Pharmaceuticals, Inc.
$35
PharmaEssentia USA Corporation
$34
Ipsen Biopharmaceuticals, Inc
$34
TAIHO ONCOLOGY, INC.
$31
ABBVIE INC.
$29
Eisai Inc.
$26
Coherus Biosciences Inc.
$25
Merck Sharp & Dohme LLC
$24
Bayer Healthcare Pharmaceuticals Inc.
$24
Gilead Sciences, Inc.
$23
SOBI, INC
$22
ACCORD HEALTHCARE, INC.
$20
Top 3 companies account for 35.5% of 2024 payments
All-time payments by company (2018-2024) ›
Becton, Dickinson and Company
$4,700
Novartis Pharmaceuticals Corporation
$2,864
NOVARTIS PHARMACEUTICALS CORPORATION
$1,353
Merck Sharp & Dohme Corporation
$779
AstraZeneca Pharmaceuticals LP
$711
Amgen Inc.
$683
E.R. Squibb & Sons, L.L.C.
$568
PFIZER INC.
$552
Pharmacyclics LLC, An AbbVie Company
$491
Genentech USA, Inc.
$418
Astellas Pharma US Inc
$417
Janssen Biotech, Inc.
$310
Bayer HealthCare Pharmaceuticals Inc.
$303
Teva Pharmaceuticals USA, Inc.
$286
Takeda Pharmaceuticals U.S.A., Inc.
$276
Blueprint Medicines Corporation
$274
Lilly USA, LLC
$253
Puma Biotechnology, Inc.
$248
Epizyme, Inc.,
$243
Exelixis Inc.
$232
GENZYME CORPORATION
$210
Merck Sharp & Dohme LLC
$195
GlaxoSmithKline, LLC.
$178
Seattle Genetics, Inc.
$154
Gilead Sciences, Inc.
$152
Daiichi Sankyo Inc.
$143
AVEO Pharmaceuticals, Inc.
$142
Karyopharm Therapeutics Inc.
$137
Seagen Inc.
$131
Celgene Corporation
$128
Alexion Pharmaceuticals, Inc.
$125
Incyte Corporation
$99
Pharmacyclics LLC, an AbbVie Company
$94
Ipsen Biopharmaceuticals, Inc
$89
Mirati Therapeutics, Inc.
$86
Otsuka America Pharmaceutical, Inc.
$76
Bayer Healthcare Pharmaceuticals Inc.
$72
Dova Pharmaceuticals
$68
Taiho Oncology, Inc.
$65
PharmaEssentia USA Corporation
$63
Clovis Oncology, Inc.
$62
Janssen Pharmaceuticals, Inc
$58
EISAI INC.
$58
Eisai Inc.
$56
BeiGene USA, Inc.
$55
Coherus Biosciences Inc.
$48
JAZZ PHARMACEUTICALS INC.
$48
PUMA BIOTECHNOLOGY, INC.
$47
INSYS Therapeutics Inc
$41
Boehringer Ingelheim Pharmaceuticals, Inc.
$40
Shire North American Group Inc
$33
TerSera Therapeutics LLC
$32
TAIHO ONCOLOGY, INC.
$31
Foundation Medicine, Inc.
$30
BTG International, Inc.
$30
ABBVIE INC.
$29
ImmunoGen, Inc.
$28
Shionogi Inc
$26
ADC Therapeutics America, Inc.
$25
SERVIER PHARMACEUTICALS LLC
$25
AMAG Pharmaceuticals, Inc.
$24
Kyowa Kirin, Inc.
$24
Pharmacosmos Therapeutics Inc.
$24
AbbVie, Inc.
$23
Myovant Sciences Inc.
$22
Octapharma USA, Inc.
$22
SOBI, INC
$22
EMD Serono, Inc.
$22
ACCORD HEALTHCARE, INC.
$20
Deciphera Pharmaceuticals Inc.
$20
Regeneron Healthcare Solutions, Inc.
$20
Janssen Scientific Affairs, LLC
$19
R-Pharm US LLC
$19
EUSA Pharma (US) LLC
$19
Spectrum Pharmaceuticals Inc.
$19
Rigel Pharmaceuticals, Inc.
$18
Helsinn Therapeutics (U.S.), Inc.
$18
TOLMAR Pharmaceuticals, Inc.
$17
Emmaus Medical, Inc.
$16
Array BioPharma Inc.
$15
AbbVie Inc.
$12
Top 3 companies account for 45.5% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AKYNZEO · ALIMTA · AYVAKIT · Abraxane · Alecensa · Aliqopa · Aranesp · BALVERSA · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · Braftovi · CABLIVI · CALQUENCE · CAMCEVI · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELREXFIO · EMEND · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · EXKIVITY · Elahere · Endari · Enhertu · FERAHEME · FOTIVDA · FOUNDATIONONE · Folotyn · GAUCHER-DISEASE · GAVRETO · GILOTRIF · HERZUMA · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Ixempra · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · Mulpleta · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · ONCASPAR · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · PADCEV · PANZYGA · PIQRAY · PROMACTA · Perjeta · Polivy · QINLOCK · REBLOZYL · RETACRIT · RETEVMO · RYDAPT · Revlimid · Rituxan Hycela · Rubraca · SANCUSO · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SPRYCEL · SYNDROS · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TUKYSA · Tavalisse · Tazverik · Trodelvy · Truxima · ULTOMIRIS · Udenyca · Ultomiris · VARUBI · VENCLEXTA · VERZENIO · VORAXAZE · VPRIV · Vectibix · Venclexta · Vitrakvi · XARELTO · XPOVIO · XTANDI · Xofigo · ZEJULA · ZEPZELCA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (60%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
116
Per 100K population
3.5
County median income
$102,285
Nearest hospital
SHARP CHULA VISTA MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Johnson is a mixed practice specialist, with above-average Medicare volume (top 3% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Johnson experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Johnson performed 90,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Johnson receive payments from pharmaceutical companies?
Yes. Dr. Johnson received a total of $19,582 from 81 companies across 600 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Johnson's costs compare to other hematology & oncology specialists in Chula Vista?
Dr. Johnson's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Johnson) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Chula Vista
Browse hematology & oncology specialists in Chula Vista ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Becton, Dickinson and Company Payments to Doctors
See all physicians who received payments from Becton, Dickinson and Company.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
NOVARTIS PHARMACEUTICALS CORPORATION Payments to Doctors
See all physicians who received payments from NOVARTIS PHARMACEUTICALS CORPORATION.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology